Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 1—January 2013
Research

Seroepidemiologic Effects of Influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore

James M. TrauerComments to Author , Don Bandaranayake, Robert Booy, Mark I. Chen, Michelle Cretikos, Gary K. Dowse, Dominic E. Dwyer, Michael E. Greenberg, Q. Sue Huang, Gulam Khandaker, Jen Kok, Karen L. Laurie, Vernon J. Lee, Jodie McVernon, Scott Walter, Peter G. Markey, and for the Australia, New Zealand and Singapore Pandemic Serosurveillance Study Group
Author affiliations: Author affiliations: Melbourne Sleep Disorders Centre, East Melbourne, Victoria, Australia (J.M. Trauer); Environmental Science and Research, Wallaceville, New Zealand (D. Bandaranayake, Q.S. Huang); National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia (R. Booy, G. Khandaker); National University Health System, Singapore (M.I. Chen); University of Sydney, Sydney, New South Wales, Australia (M. Cretikos); Communicable Disease Control Directorate, Shenton Park, Western Australia, Australia (G.K. Dowse); Centre for Infectious Diseases and Microbiology, Westmead (D.E. Dwyer, J. Kok); CSL Limited, Parkville, Victoria, Australia (M.E. Greenberg); World Health Organization Collaborating Centre for Reference and Research in Influenza, North Melbourne, Victoria, Australia (K.L. Laurie); World Health Organization, Geneva, Switzerland (V.J. Lee); Melbourne School of Population Health, Parkville (J. McVernon); Centre for Epidemiology and Research, North Sydney, New South Wales, Australia (S. Walter; Centre for Disease Control, Tiwi, Northern Territory, Australia (P.G. Markey)

Main Article

Table 4

Multivariate logistic regression models on outcome of pre- and postpandemic seropositivity in community-based studies of influenza A (H1N1) 2009 in the Southern Hemisphere with exposure variables of region, age group, and sex, winter 2009*

Exposure variable Prepandemic phase, n = 4,289
 Postpandemic phase, n = 5,650
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Region
New South Wales† 1 1
New Zealand 1.18 (0.77–1.80) 0.45 1.44 (1.17–1.79) 0.001
Northern Territory 0.62 (0.38–1.02) 0.06 0.82 (0.66–1.01) 0.06
Queensland 1.25 (0.79–1.98) 0.34 0.78 (0.53–1.14) 0.20
Singapore 0.40 (0.27–0.61) <0.001 0.56 (0.43–0.74) <0.001
Tasmania 1.50 (0.95–2.35) 0.08
Victoria 1.37 (0.94–2.01) 0.11
Western Australia
 0.41 (0.25–0.67)
 <0.001
1.04 (0.76–1.43)
 0.79
Age group, y
0–4† 1 1
5–14 2.34 (0.92–5.92) 0.07 1.60 (1.24–2.06) <0.001
15–34 13.70 (5.85–32.07) <0.001 1.50 (1.18–1.91) 0.001
35–54 6.24 (2.50–15.57) <0.001 0.75 (0.58–0.98) 0.04
55–74 14.60 (5.98–35.62) <0.001 0.73 (0.56–0.95) 0.02
≥75
47.43 (18.58–121.08)
 <0.001
0.95 (0.64–1.41)
 0.80
Sex
F† 1 1
M 0.99 (0.73–1.34) 0.96 0.97 (0.85–1.24) 0.70
Unknown 2.44 (1.74–3.42) <0.001 1.67 (1.25–2.24) 0.001

*Blank cells indicate no data. The 2 regression models are displayed vertically.
†Reference category.

Main Article

1A list of the group’s members can be found at the end of this article.

Page created: December 20, 2012
Page updated: December 20, 2012
Page reviewed: December 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external